Breast Cancer Therapeutics Market Analysis

Breast Cancer Therapeutics Market Analysis

To get key market trends

  Download Free Sample

Based on therapy type, the market is segmented into targeted therapy, hormonal therapy, chemotherapy and immunotherapy. The targeted therapy segment exceeded USD 19 Billion in 2022 anticipating a substantial growth in coming years. This substantial market dominance is attributed to its adaptability for combination with other treatments, the emergence of personalized approaches to enhance clinical outcomes, and continuous advancements.
 

• Ongoing clinical studies have widened the scope of targeted therapies to include multiple molecules in targetable pathways including the epidermal growth factor receptor (EGFR), poly (adenosine diphosphate-ribose) polymerase (PARP), and cyclin-dependent kinase 4/6 (CDK4/6).
   
• Further, developments in treatment for metastatic hormone receptor-positive breast cancer have promoted the use of targeted therapies. Majority of the treatment guidelines, including the National Comprehensive Cancer Network suggests the use of targeted therapeutic options with artificial intelligence or selective ER modulators rather than chemotherapy.
   

The North America breast cancer therapeutics market is expected to grow at 6.8% during the analysis period.
 

• This dominant market share is attributable to several factors such as the high incidence of breast cancer, steadily rising disease burden, and presence of major market players among others. According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases. The Globocan 2020 reported that the incidence of breast cancer was 253,465 cases in the U.S. Thus, the high incidence and prevalence of breast cancer inflicts significant mortality along with disease burden. The rising disease burden in the country is anticipated to promote the demand for breast cancer therapeutics.
   
• Further, the presence of major market players and favorable reimbursement scenario for breast cancer treatment would drive the acceptance rate of breast cancer therapeutics.